Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 5/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31201814 | 1.00 | TDP1 (0.44) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL4798674 | 0.93 | EPHX2 (0.42) | TDP1 | |
| SCHEMBL18313972 | 0.86 | TDP1 (0.48) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL6386900 | 0.84 | MAOA (0.36) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL12463596 | 0.84 | MEN1 (0.39) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL26048445 | 0.84 | TDP1 (0.51) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL25196839 | 0.83 | TDP1 (0.54) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL8358630 | 0.82 | TDP1 (0.52) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL26444510 | 0.82 | CA14 (0.44) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL18865427 | 0.81 | TDP1 (0.55) | TDP1MAOAMAOBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786468-B2 | Nanoparticles | KING'S COLLEGE LONDON (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11786468-B2 | Nanoparticles | KING'S COLLEGE LONDON (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11369697-B2 | Liposome nanoparticles for tumor magnetic resonance imaging | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-06-28 | — | — | US | disclosed |
| US-20180177728-A1 | NANOPARTICLES | KING'S COLLEGE LONDON (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180178043-A1 | FOCUSTED ULTRASOUND HYPERTHERMIA | KING'S COLLEGE LONDON (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180177728-A1 | NANOPARTICLES | KING'S COLLEGE LONDON (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180178043-A1 | FOCUSTED ULTRASOUND HYPERTHERMIA | KING'S COLLEGE LONDON (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20170348440-A1 | Novel Liposome Nanoparticles for Tumor Magnetic Resonance Imaging | MEDICAL RESEARCH COUNCIL (GB) | 2017-12-07 | — | — | US | disclosed |
| US-20170348440-A1 | Novel Liposome Nanoparticles for Tumor Magnetic Resonance Imaging | MEDICAL RESEARCH COUNCIL (GB) | 2017-12-07 | — | — | US | disclosed |
| WO-2016198862-A1 | NANOPARTICLES | KING'S COLLEGE LONDON (GB) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016198864-A1 | FOCUSED ULTRASOUND HYPERTHERMIA | KING'S COLLEGE LONDON (GB) | 2016-12-15 | — | — | WO | disclosed |
| US-20130129636-A1 | Novel Liposome Nanoparticles for Tumor Magnetic Resonance Imaging | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130129636-A1 | Novel Liposome Nanoparticles for Tumor Magnetic Resonance Imaging | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20100297023-A1 | Lipid | IMUTHES LIMITED UNIVERSITY OF THE WITWATERSRAND | 2010-11-25 | — | — | US | disclosed |
| US-20050287202-A1 | Compound | MILLER ANDREW D | 2005-12-29 | — | — | US | disclosed |
| EP-0861228-B1 | LIPOPOLYAMINES AS TRANSFECTION AGENTS AND PHARMACEUTICAL USES THEREOF | AVENTIS PHARMA SA (FR) | 2000-08-23 | — | — | EP | disclosed |
| EP-0861228-A1 | LIPOPOLYAMINES AS TRANSFECTION AGENTS AND PHARMACEUTICAL USES THEREOF | Aventis Pharma S.A. (FR) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997018185-A1 | LIPOPOLYAMINES AS TRANSFECTION AGENTS AND PHARMACEUTICAL USES THEREOF | RHONE-POULENC RORER S.A. (FR) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369697-B2 | Liposome nanoparticles for tumor magnetic resonance imaging | PHOSPHO1, SGMS1, SGMS2 | TDP1 3790/4885MAOA 4439/4885MAOB 4502/4885 |
| US-20050287202-A1 | Compound | FOLR1, FOLR2, LDLR | TDP1 4664/4885MAOA 775/4885MAOB 407/4885 |
| US-20180177728-A1 | NANOPARTICLES | FUS, LIPA, PLIN3 | TDP1 1714/4885MAOA 3191/4885MAOB 3069/4885 |
| US-20100297023-A1 | Lipid | NR1H2, NR1H3, NR1H4 | TDP1 4830/4885MAOA 4722/4885MAOB 4552/4885 |
| US-20180178043-A1 | FOCUSTED ULTRASOUND HYPERTHERMIA | FUS, FABP3, FABP4 | TDP1 1016/4885MAOA 3645/4885MAOB 3425/4885 |
| US-11786468-B2 | Nanoparticles | FUS, LIPA, PLIN3 | TDP1 1714/4885MAOA 3191/4885MAOB 3069/4885 |
| US-20130129636-A1 | Novel Liposome Nanoparticles for Tumor Magnetic Resonance Imaging | PHOSPHO1, SGMS1, SGMS2 | TDP1 4145/4885MAOA 4624/4885MAOB 4656/4885 |
| US-20170348440-A1 | Novel Liposome Nanoparticles for Tumor Magnetic Resonance Imaging | PHOSPHO1, SGMS1, SGMS2 | TDP1 3901/4885MAOA 4325/4885MAOB 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.